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Available online 1 December 2015Background:Abnormalities inmembrane excitability andNa+ channel function are characteristic of amyotrophic
lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+
channel blocker and membrane stabiliser ﬂecainide in ALS.
Methods: A double-blind, placebo-controlled, randomised clinical trial of ﬂecainide (200 mg/day) for 32-weeks
with a 12-week lead-in phase was conducted in participants with probable or deﬁnite ALS recruited from mul-
tiple Australian centres (ANZCT Registry number ACTRN12608000338369). Patients were reviewed by a cardiol-
ogist to rule out cardiac contraindications. Participants were randomly assigned (1:1) to ﬂecainide or placebo
using stratiﬁed permuted blocks by a central pharmacy. The primary outcome measure was the slope of decline
of the ALS Functional Rating Scale-revised (ALS FRS-r) during the treatment period.
Findings: Between March 11, 2008 and July 1, 2010, 67 patients were screened, 54 of whom were randomly
assigned to receive ﬂecainide (26 patients) or placebo (28 patients). Four patients in the ﬂecainide group and
three patients in the placebo group withdrew from the study. One patient in the ﬂecainide group died during
the study, attributed to disease progression. Flecainide was generally well tolerated, with no serious adverse
events reported in either group. There was no signiﬁcant difference in the rate of decline in the primary outcome
measure ALS-FRS-r between placebo and ﬂecainide treated patients (Flecainide 0.65 [95% CI 0.49 to 0.98]; Place-
bo 0.81 [0.49 to 2.12] P = 0.50). However, the rate of decline of the neurophysiological index was signiﬁcantly
reduced in the ﬂecainide group (Flecainide 0.06 [0.01 to 0.11]; Placebo 0.14 [0.09 to 0.19], P = 0.02). Placebo-
treated patients demonstrated greater CMAP amplitude reduction during the course of the study in the subset
of patients with a reduced baseline CMAP amplitude (Flecainide:−15 ± 12%; Placebo−59 ± 12%; P = 0.03).
Flecainide-treated patients maintained stabilized peripheral axonal excitability over the study compared to
placebo.
Interpretation: This pilot study indicated that ﬂecainide was safe and potentially biologically effective in ALS.
There was evidence that ﬂecainide stabilized peripheral axonal membrane function in ALS. While the study
was not powered to detect evidence of beneﬁt of ﬂecainide on ALS-FRS-r decline, further studies may demon-
strate clinical efﬁcacy of ﬂecainide in ALS.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Neuroprotection1. Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and in-
variably fatal neurodegenerative disorder of motor neurons (Kiernan
et al., 2011). There is currently no cure and a critical need to develop
disease-modifying therapies. Multiple pathophysiological mechanisms4 Mallett Street, Camperdown
. Kiernan).
. This is an open access article underunderlie the development of ALS, including abnormalities inmembrane
excitability and ion channel function (Kiernan et al., 2011). Hyperexcit-
ability and consequent excitotoxicity have been extensively document-
ed in ALS and may be linked to the process of neurodegeneration
(Mogyoros et al., 1998; Kuo et al., 2005; Kanai et al., 2006; Vucic and
Kiernan, 2006; Vucic and Kiernan, 2010). Peripheral axonal excitability
techniques demonstrated elevated persistent Na+ and reduced K+
conductances (Kanai et al., 2006; Vucic and Kiernan, 2006), a neuro-
physiological proﬁle that would promote hyperexcitability, membrane
instability and spontaneous activity. Increased persistent Na+ conduc-
tances and consequent hyperexcitability are also characteristic of ALSthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Trial design: Diagram demonstrating the 12-week lead-in period followed by ran-
domization at the 4th visit (week 12), with the ﬁnal visit occurring 32 weeks after
randomization.
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Quinlan et al., 2011).
Aberrant excitability and upregulation of persistent Na+ conduc-
tances have been postulated to lead to an increase in intracellular Na+
concentration, overwhelming the corrective effects of the Na+/K+
pump and the Na+/Ca2+ transporter, and resulting in motor neuron
neurodegeneration via Ca2+-mediated processes (Kapoor et al., 2003;
Stys, 2005). Consequently, promotion of membrane stability, ion ho-
meostasis and antagonism of persistent Na+ conductances may be
neuroprotective in ALS. Riluzole, a neuroprotective agent that prolongs
survival in ALS, partially blocks persistent Na+ conductances in ALS
mouse models (Benoit and Escande, 1991; Urbani and Belluzzi, 2000;
Kuo et al., 2005), relevant at clinical doses. Conversely, it has been sug-
gested that axonal hyperexcitability may be an adaptive mechanism
promoting neuroprotection in ALS. Speciﬁcally, enhancing neuronal
hyperexcitability was reported to protect motor neurons from endo-
plasmic reticulum stress and subsequent degeneration (Saxena et al.,
2013). Accordingly, it was postulated that targeting hyperexcitability
via Na+ channel modulation as a therapeutic strategy may not be
beneﬁcial, perhaps producing adverse effects in motor neurons.
Flecainide is a well-characterized membrane stabilizer and Na+
channel blocking agent, particularly used in the context of cardiac
medicine (Aliot et al., 2011). Studies in animal models have demon-
strated that ﬂecainide may exert neuroprotective beneﬁts (Bechtold
et al., 2005; Morsali et al., 2013). In light of this background, the aim
of the present study was to examine the neuroprotective potential of
ﬂecainide and its impact on membrane excitability and function in
ALS patients.
2. Methods
2.1. Study Design and Participants
This trial was an investigator-initiated, double-blind, placebo-
controlled and randomized clinical trial of ﬂecainide treatment in ALS
patients. Participants were recruited from multiple centres around
Australia between March 2008 and July 2010 and all investigations
were undertaken at a specialist ALS clinic.
Participants were eligible for inclusion in the trial if they were aged
between 18 and 75 years, with a probable or deﬁnite diagnosis of ALS
according to the revised El Escorial criteria (Brooks et al., 2000) and a
disease duration of less than 5 years. Other inclusion criteria were a
sniff nasal inspiratory pressure (SNIP) of greater than 50% predicted,
normal cardiac rhythm and normal left ventricular function (deter-
mined by echocardiography) and ability to provide informed consent.
Patients with a history of dementia or psychiatric illness, cardiac
disease, signiﬁcant impairment of hepatic or renal function or who
were pregnant or lactating were excluded.
All patients provided written informed consent, with studies
approved by the South Eastern Sydney and Illawarra Area Health
Service Human Research Ethics Committee (Northern Sector). Approval
was obtained from the Australian Therapeutic Goods Administration for
the use of ﬂecainide in the current trial. This study was registered with
Australian and New Zealand Clinical Trials Registry under the number
ACTRN12608000338369, and supported by the National Health and
Medical Research Council of Australia (Project number #568743).
The trial was composed of a 12-week lead-in period comprised of
three consecutive visits at 4 weekly intervals, enabling a calculation of
the baseline rate of decline in ALSFRS-R to be determined (Fig. 1).
During the lead-in period, all patients were formally reviewed by a car-
diologist to rule out cardiac contraindications prior to receiving
ﬂecainide. All patients included in the study had normal cardiac rhythm
and left ventricular function, determined by electrocardiography, with-
out history of cardiac disease. All patients continued to receive riluzole
(50 mg twice daily). Once randomized, patients entered the 32 week
treatment period and were assessed every 8 weeks.2.2. Randomisation and Masking
Participants were randomly assigned (1:1) to ﬂecainide or placebo
using permuted blocks stratiﬁed by disease onset site (bulbar or limb-
onset). Randomization occurred after the non-treatment lead-in period
at visit 4 (week 12). All randomizations were performed centrally by a
speciﬁc clinical trials pharmacist in the Department of Pharmacy, Prince
of Wales Hospital. Patients were initially prescribed ﬂecainide 50 mg
twice daily for one week and subsequently the dose was increased to
100 mg twice daily. Drug was supplied by Alphapharm Australia,
while placebo was supplied by Stenlake Science and Nature, Australia.
Drug and placebo were identical in appearance and were dispensed
by the pharmacy at 8 weekly intervals during the treatment period.
All investigators, assessors and evaluators remained blinded to
treatment.
2.3. Primary Outcome
The primary outcome measure was the slope of decline of the ALS
Functional Rating Scale-revised (ALS FRS-r) during the treatment
period. The ALSFRS-r is a validated measure of functional impairment
in ALS, with higher scores indicating better function (Range 0–48).
The ALSFRS-r is divided into 4 subscores of 12 points each (bulbar,
ﬁne motor, gross motor and respiratory) (Cedarbaum et al., 1999).
2.4. Secondary Endpoints
Secondary endpoints included safety and tolerability, patient func-
tion (quality of life, grip and motor function, respiratory performance)
and neurophysiological assessments as detailed below. At each study
visit, any possible adverse events were documented. All patients
underwent blood screening to assess liver, renal and haematological
function at each 8weekly review.Monitoring of adverse events was un-
dertaken by an independent data safety committeewhich reviewed and
analysed all data at the 6 and 12 month study timelines.
Health-related quality of life was assessed via the Short Form-36
(SF-36) questionnaire. Walking ability was assessed via the time in sec-
onds to undertake a 6-m walk, with the fastest time recorded out of
three attempts (Tiedemann et al., 2008). Grip strength was assessed
by a Jaymar dynamometer (Asimow Engineering Co; Los Angeles, CA,
USA) using the average of three trials for each hand. Respiratory func-
tion was assessed via forced vital capacity (FVC) and sniff nasal inspira-
tory pressure (SNIP). FVC was measured using a portable spirometer
(MicroLab, CareFusion; Basingstoke, UK), using the best of three trials
and reported as a percentage of the predicted value (Miller et al.,
2005). SNIP was measured using the MicroRPM device (CareFusion;
Basingstoke, UK) as a percentage of the predicted value by age and sex
(Fitting et al., 1999; Cheah et al., 2009). The highest sniff pressure (cm
H2O) from a minimum of 10 short sniffs through each nostril was
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age and sex, calculated using the formula previously derived by Fitting
et al. (Fitting et al., 1999) andutilised as in Cheah et al. (Cheah et al., 2009).
The neurophysiological index was calculated for the ulnar nerve,
recording compoundmuscle action potentials (CMAPs) from the abduc-
tor digiti minimi (ADM), according to previously reported techniques
(Swash and de Carvalho, 2004). Peripheral motor axonal excitability
studies were undertaken, utilising standardized threshold tracking
protocols (Kiernan et al., 2000) and QTracW software (© Institute of
Neurology, UK). The median nerve was stimulated at the wrist, record-
ing CMAPs from the abductor pollicis brevis (APB) muscle. Cortical
excitability studieswere performed using threshold tracking transcrani-
al magnetic stimulation (TMS) according to a previously described
method (Vucic et al., 2006). Peripheral (N=32) and cortical excitability
studies (N= 22) were analysed at two time points — prior to random-
ization and at 32 weeks post-randomization.
2.5. Statistical Analysis
The primary analysis compared the rate of decline of ALSFRS-R
between treatment and placebo arms, adjusted for patient-speciﬁc
pre-treatment slope, using mixed models analysis where the intercept
for each patient is random and the slopes are ﬁxed effects, after deter-
mining that there were no treatment-by-time interactions. As bulbar
and respiratory ALSFRS-R subscores did not decline signiﬁcantly these
variables were summarised by means rather than rate of decline. The
sample size was calculated to be 100 patients to provide 80% power to
detect a 25% change in rate of ALS FRS-r decline, accounting for 20%
patient drop-out. Differences betweenmeans for peripheral and cortical
excitability metrics were assessed using t-tests when normally distrib-
uted and Wilcoxon signed-rank tests when not normally distributed.
Statistical analysis was performed in SAS 9.2 (USA) and SPSS (Version
22, IBM, USA). A two sided P value of ≤0.05 was considered signiﬁcant.
3. Results
3.1. Study Participants
In total, 67 ALS patients were screened for inclusion in the study be-
tweenMarch 2008 and July 2010 (Fig. 2). One patientwas ineligible and
12 patients were unable to participate in the study visit schedule. 54
patients were randomized after the 12 week lead-in period and com-
menced on the assigned medication with 26 patients (54.2 ± 9.8
years; 16 males) allocated to the ﬂecainide group and 28 to the placeboFig. 2. Patient ﬂow chart: Trial schematic, with the number of participangroup (53.5 ± 10.6 years; 16 males; Fig. 2). Four patients from the
ﬂecainide group withdrew consent, one due to side-effects and three
as they felt the medication was ineffective. Three patients from placebo
group withdrew consent as they felt no beneﬁt from treatment. One
patient in the ﬂecainide group died during the study, and this was at-
tributed to ALS disease progression. The population for the intention-
to-treat analysis was the total population included in the trial (N=54).
Patients in the two groups exhibited similar demographic and clini-
cal characteristics, as well as respiratory and neurophysiological
features (Table 1). The median ALSFRS-r score in the entire cohort was
41 (range 36–42), corresponding to mild functional impairment. At
the timeof study entry, onepatient from theplacebo groupwasutilising
non-invasive ventilation at night and no patients had a gastrostomy
tube. In total, 13 of 54 patients had bulbar onset ALS (Table 1), with
38 of 41 limb onset patients reporting functional difﬁculties with
upper limbs or demonstrating electrophysiological evidence of upper
limb disease. The remaining 3 patients (2 ﬂecainide; 1 placebo) did
not demonstrate evidence of upper limb abnormalities at the time of
the study. The mean serum ﬂecainide level was 0.42 ± 0.03 mg/L
(range 0.2–0.8mg/L;measured at visit 7–8) in theﬂecainide-treated co-
hort, in line with the recorded therapeutic range for cardiac use of 0.2–
1 mg/L (Tamargo et al., 2012). All placebo treated patients had a serum
ﬂecainide level of less than 0.2 mg/L.3.2. Clinical Efﬁcacy
There was no signiﬁcant difference in the rate of decline in ALSFRS-r
slope during the lead-in phase between the placebo and the ﬂecainide
group (average slope in units per month [95% CI]: Flecainide 0.58
[0.27 to 0.88]; Placebo 0.49 [0.20 to 0.79]; P=0.66). Following random-
ization, there remained no difference between the groups in the rate of
decline in the ALSFRS-r slope, after adjusting for pre-treatment decline
(Flecainide 0.65 [0.49 to 0.98]; Placebo 0.81 [0.49 to 2.12]; P = 0.50,
Table 2) and accordingly insufﬁcient evidence to suggest a difference
in the primary outcome measure between ﬂecainide and placebo
groups. Importantly, ﬂecainide therapy did not accelerate the rate of
ALS FRS-r slope, thereby suggesting that ﬂecainide-mediatedNa+ chan-
nel blockade was not detrimental to disease progression.
Analysis of ALSFRS-r subscores also did not reveal any signiﬁcant dif-
ferences between treatment groups (Table 2),with the rate of decline of
the ALSFRS-r subscores similar between treatment groups during the
lead-in phase and after randomization. There was also no difference in
rate of decline of ALSFRS-r slope between treatments for limb versus
bulbar onset subgroups (P for interaction = 0.63).ts per treatment arm and number of patients completing the study.
Table 1
Patient baseline demographic and clinical characteristics for ﬂecainide and placebo
cohorts. Results are expressed as number (%), mean ± standard deviation or median
(Q1 - Q3).
Flecainide
(N = 26)
Placebo
(N = 28)
Age at baseline (years) 54.2 ± 9.8 53.5 ± 10.6
Male/female 16/10 16/12
Disease duration (months) 23.8 (12.7–31.5) 18.6 (12.7–23.5)
Weight (kg) 75.0 ± 10.8 79.1 ± 14.5
Bulbar-onset 5 (19%) 8 (29%)
Family history of disease 5 (19%) 3 (11%)
Grip strength, stronger hand (kg) 21.5 (17.7–29.3) 21.3 (13.1–33.4)
ALSFRS-r 41.0 (38.0–42.0) 40.0 (36.0–41.5)
Sniff nasal inspiratory pressure
(% predicted)
94.8 (55.8–113.4) 76.7 (59.8–106.2)
Forced vital capacity (% predicted) 84.6 ± 15.3 83.3 ± 16.1
SF-36 physical component 35.7 ± 10.7 34.4 ± 11.1
SF-36 mental component 54.7 ± 11.2 54.4 ± 8.0
Neurophysiological index 3.0 ± 1.2 2.7 ± 1.5
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3.3.1. Neurophysiological Measures
During the treatment phase, the decline in neurophysiological index
was slowed in the ﬂecainide-treated cohort compared to the placebo
group (Fig. 3) adjusted for run-in decline. While during the lead-in
phase there was no signiﬁcant difference in the slope of decline of the
neurophysiological index between the groups (Flecainide 0.13 [0.03–
0.22]; Placebo 0.18 [0.08–0.27]; P=0.36), the rate of decline of the neu-
rophysiological index was signiﬁcantly lower in the ﬂecainide group
than in placebo during the treatment phase (Flecainide 0.06 score
points/month [0.01–0.11]; placebo 0.14 [0.09–0.19], P = 0.02, Table 2).
Peripheral axonal excitability remained relatively stable across the
treatment phase in ﬂecainide treated patients comparing baseline
values to those after 32±1weeks of treatment,with threshold electrot-
onus parameters remaining stable, along with CMAP amplitude
(Table 3). However, the placebo group demonstrated changes in a num-
ber of parameters (Table 3) including a reduction inmaximal CMAP am-
plitudes (P = 0.01) and reductions in hyperpolarizing threshold
electrotonus (All P b 0.01). In contrast, maximal CMAP was reduced
by 39 ± 11% compared to baseline in the placebo-treated group and
only by 14 ± 8% in the ﬂecainide group, although this difference did
not reach statistical signiﬁcance (P = 0.09; Fig. 4). However there
were differences in the extent of change over the 32week treatment pe-
riod between placebo and ﬂecainide treated groups on a number of
excitability parameters (Table 3; Hyperpolarising threshold electroto-
nus; Current threshold relationship All P b .01).
Patients were subdivided into two groups— those with a preserved
baseline maximal CMAP amplitude (N5 mV) and those with a reduced
CMAP amplitude (≤5 mV) at study baseline, as in prior studies (Kanai
et al., 2006). In patients with a reduced CMAP amplitude at baselineTable 2
Analysis of primary and secondary outcome measures. Intention-to treat analysis in 54 ALS pa
Sclerosis Functional Rating Scale-revised (ALS FRS-r) slope. Results are expressed as mean mon
Outcome measure Mean monthly rate of
Flecainide
ALS FRS-r 0.65 (0.32–0.98)
ALS FRS-r Fine Motor subscore 0.19 (0.06–0.32)
ALS FRS-r Gross Motor subscore 0.21 (0.09–0.33)
Sniff nasal inspiratory pressure (% predicted) 1.90 (1.02–2.78)
Forced vital capacity 1.25 (0.58–1.92)
6-metre walking test 0.26 (0.22–0.73)
Strongest grip strength at baseline 0.95 (0.50–1.4)
SF-36 physical component summary 0.64 (0.24–1.04)
SF-36 mental component summary 0.1 (0.43–0.64)
Neurophysiological index 0.06 (0.01–0.11)(N=16), placebo-treated patients demonstrated a signiﬁcantly greater
decline in CMAP amplitude (59 ± 12%) compared to ﬂecainide-treated
patients (15± 12%; P= 0.03; Fig. 4). This differencewas not evident in
ﬂecainide and placebo-treated patients with a preserved CMAP at base-
line (N = 16; ﬂecainide 12.9 ± 12%; placebo 17.8 ± 15%; P = 0.80).
Threshold tracking TMS studies demonstrated that short interval
intracortical inhibition (SICI) was not signiﬁcantly modulated by
ﬂecainide during the treatment phase (Baseline SICI 2.8 ± 2.0%; After
treatment SICI 2.4 ± 2.5%, P = 0.78) and remained reduced compared
to normal values. Similarly, intracortical facilitation remained relatively
stable (Baseline ICF -0.87 ± 1.8%; After treatment ICF−2.7 ± 2.8; P =
0.65), with no differences evident following ﬂecainide treatment.
3.3.2. Functional Outcome Measures
The rate of decline in functional outcome measures was not signiﬁ-
cantly different between ﬂecainide and placebo groups for the 6-
metrewalking test (P=0.32), grip strength (P=0.73), physical quality
of life (P= 0.98) or mental quality of life (P= 0.47; Table 2). Similarly,
analysis of respiratory measures did not identify signiﬁcant differences
in the rate of decline in slope of forced vital capacity (P = 0.38,
Table 2) and SNIP (P = 0.13, Table 2).
3.4. Safety and Tolerability
Flecainide was generally well tolerated. No serious adverse
events were reported in either group. Importantly there were no severe
cardiac adverse events recorded. Chest pain was reported by one
ﬂecainide-treated patient and two placebo-treated patients during the
course of the trial. Palpitations were reported by two ﬂecainide and
two placebo-treated patients. Treatment was discontinued following
cardiologist review in the ﬂecainide-treated patient who experienced
an episode of chest pain because physical disability prevented the un-
dertaking of a cardiac stress test to rule out ischemic heart disease. A
further ﬂecainide-treated patient underwent cardiologist review due
to an episode of dizziness to exclude arrhythmia and was continued
on ﬂecainide treatment.
The overall incidence of adverse events was similar between the
groups (Table 4). 100% of ﬂecainide patients and 88% of placebo treated
patients reported an adverse event. None of these adverse events were
directly attributable to ﬂecainide. Adverse events reported in prior
studies of ﬂecainide in the cardiac setting have included dizziness, trem-
or, nausea and diarrhoea (Clementy et al., 1992). In the present study,
dizziness was reported by 38% of ﬂecainide-treated patients compared
to 23% of placebo-treated patients, with nausea reported in 21% of
ﬂecainide-treated patients compared to 12% of placebo treated patients.
Rates of tremor and diarrhoea were very similarly reported between
ﬂecainide and placebo-treated patients (Table 4). Excessive sleepiness
was reported in 50% of ﬂecainide-treated patients compared to 19% of
placebo-treated patients.tients. The primary outcome measure was the rate of decline in the Amyotrophic Lateral
thly rate of change (95% conﬁdence interval).
change (95% CI) P-value of treatment effect
Placebo
0.81 (0.49–1.12) 0.50
0.31 (0.18–0.43) 0.19
0.28 (0.16–0.39) 0.39
2.80 (1.99–3.6) 0.13
1.64 (1.03–2.26) 0.38
0.58 (0.13–1.04) 0.32
1.06 (0.61–1.51) 0.73
0.65 (0.28–1.01) 0.98
0.36 (0.14–0.85) 0.47
0.14 (0.09–0.19) 0.02
Fig. 3. Neurophysiological index changes in ﬂecainide and placebo treated patients: The
rate of decline in the neurophysiological index was smaller for the ﬂecainide group than
the placebo-treated cohort.
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This double-blind, placebo-controlled randomised study was
designed to determine the neuroprotective potential of theNa+ channel
blocker ﬂecainide in patients with ALS. Flecainide did not produce sig-
niﬁcant adverse effects in ALS patients. While the study did not provide
evidence of improvement in the primary outcome measure, the rate of
decline in the ALS-FRS-r slope, there was also no evidence of an adverse
effect mediated by Na+ channel blockade. There was no improvement
in the clinical secondary outcome measures such as grip strength, 6-
metre walk test or respiratory measures. However, the rate of decline
in the slope of the neurophysiological index, a biomarker of lower
motor neuron dysfunction, was signiﬁcantly reduced in the ﬂecainide
group. Further, peripheral axonal excitability parameters demonstrated
signiﬁcant changes in placebo-treated patients but remained stable in
ﬂecainide-treated patients, suggesting that ﬂecainide stabilised periph-
eral axonal function in ALS.
4.1. Flecainide as a Neuroprotective Strategy
Flecainide, a class Ic antiarrhythmic agent, is a strong blocker of
persistent late Na+ currents produced by Nav1.5 channels in cardiac
tissue, blocking Na+ channels in open conformation (Aliot et al.,
2011). The rational for the potential of ﬂecainide as a neuroprotective
strategy in ALS is based on the deleterious consequences of disturbed
membrane excitability on axonal function and integrity. Excessive excit-
ability and accumulation of intra-axonal Na+ ions may potentiallyFig. 4. Peripheral axonal excitability ﬁndings inﬂecainide treated patients versus placebo:A Stim
line and follow-up recordings inﬂecainide (left) and placebo (right) treated patients.BDecline i
patients with less than or equal to 5 mV CMAP at the baseline recording.initiate a cascade, leading to axonal degeneration via reverse operation
of the Na+/Ca2+ exchanger and excess Ca2+ entry (Stys, 2005). Block-
ade of sodium channels may promote neuroprotection by preventing
the accumulation of Na+ in the axon. Accordingly, Na+ channel block-
ade has been trialed as amethod of neuroprotection in a number of neu-
rological disorders including multiple sclerosis, spinal cord injury and
stroke (Schwartz and Fehlings, 2001). The only medication currently
approved to treat ALS, riluzole, has also been demonstrated to inhibit
voltage-gated Na+ currents, with effects on fast and inactivating
currents, interacting with Nav1.6 sodium channel isoforms (Sierra
Bello et al., 2012; Vucic et al., 2014), among other effects.
Recent studies have suggested that increased excitability may be
adaptive, raising the possibility that modulation of excitability in ALS
patients may have deleterious consequences for motor neuron integrity
(Saxena et al., 2013). The present results do not suggest that treatment
with a potent Na+ channel blocking agent, which would reduce axonal
excitability, leads to enhanced peripheral neurodegeneration in ALS.
Similarly, a recent trial of the Na+ channel blocker mexiletine in ALS
did not demonstrate any decline in functional status associated with
Na+ channel blockade (Shibuya et al., 2015). Further, there is in vitro
evidence that Na+ channel modulation is neuroprotective in ALS, with
neuronal hyperexcitability and subsequent motor neuron death
prevented by Na+ channel blockers in spinal cord cultures (Fritz et al.,
2013).
4.2. Neurophysiological Markers of Disease Burden in ALS
In the present study, measures of peripheral disease burden and
membrane excitability demonstrated greater stability in ﬂecainide-
treated patients compared to the placebo cohort, suggesting a biological
effect of ﬂecainide at the level of the peripheral nerve. The neurophysi-
ological index is a sensitive surrogatemarker of ALS disease progression
(Swash and de Carvalho, 2004). In previous ALS trials neurophysiologi-
cal parameters demonstrated signiﬁcant change over time, with the
neurophysiological index declining 3.6% per month (de Carvalho et al.,
2010) or 18.3% in 12 weeks (Cheah et al., 2011). Neurophysiological
markers often decline more rapidly than clinical measures (Gordon
et al., 2007), demonstrating greater responsiveness which may be
appropriate for use in clinical trials. In the present study, ﬂecainide-
treated patients demonstrated a reduced decline in the neurophysiolog-
ical index, compared to placebo-treated patients, suggesting relative
preservation of lower motor neuron function.
Similarly, peripheral axonal excitability studies demonstrated
changes in ﬂecainide treated patients compared to placebo. Placebo-
treated patients demonstrated a shift in threshold electrotonus and
current/threshold relationship parameters over the 32-week treatmentulus response curve of stimulus current (mA) versusmaximal CMAP (mV) between base-
nmaximal CMAPnormalized to baseline values inﬂecainide (black) andplacebo (red) treated
Table 3
Peripheral axonal excitability ﬁndings. Axonal excitability parameters and functional assessment parameters in ﬂecainide and placebo treated patients (N= 32) at baseline and ﬁnal fol-
low-up assessment. Data are presented as mean ± SEM or median (interquartile range).
Flecainide Placebo
Baseline Follow-up P values Baseline Follow-up P values
Peak CMAP (mV) 4.5 ± 0.7 3.8 ± 0.6 0.16 5.1 (3.8) 1.3 (5.5) 0.01
Strength–duration time constant (ms) 0.44 ± 0.02 0.44 ± 0.02 0.94 0.50 ± 0.03 0.48 ± 0.02 0.44
Hyperpolarizing threshold electrotonus
10–20 ms (%) −71.5 ± 1.0 −73.7 ± 1.5 0.25 −73.0 ± 0.9 −68.1 ± 1.5 0.002
20–40 ms (%) −88.7 ± 1.4 −91.9 ± 2.1 0.18 −91.8 ± 1.3 −84.7 ± 2.2 0.001
90–100 ms (%) −120 (37) −116 (26) 0.22 −117.8 ± 4.1 −104.6 ± 3.7 0.007
Current threshold relationship
Resting I/V slope (%) 0.6 ± 0.02 0.6 ± 0.02 0.63 0.55 ± 0.02 0.61 ± 0.02 0.02
Hyperpolarizing IV drift (%) −241 ± 14 −271 ± 15 0.002 −262 ± 11 −249 ± 14 0.24
1921S.B. Park et al. / EBioMedicine 2 (2015) 1916–1922period, an excitability proﬁle similar to that seen in ALS patients with
more severe peripheral disease burden (Kanai et al., 2006). In contrast,
ﬂecainide-treated patients maintained relatively stable peripheral
membrane excitability over 32 weeks. In the subset of patients with a
reduced CMAP (≤5 mV) amplitude at study entry, patients treated
with ﬂecainide demonstrated signiﬁcantly less reduction in CMAP
amplitude than placebo-treated patients. Peripheral excitability abnor-
malities in ALS typically progresswith time, although they are not linear
and are dependent on clinical severity (Kanai et al., 2006), with variabil-
ity reﬂecting diversity in disease onset and progression. Further, there
were no speciﬁc Na+ channel related changes in the axonal excitability
proﬁle, suggest that rather than solely acting to modulate persistent
Na+ current, ﬂecainide may stabilise membrane function in ALS
patients.
While cortical hyperexcitability is a prominent feature in ALS,
ﬂecainide failed to exert signiﬁcant modulating effects on the
parameters of cortical excitability, unlike riluzole which produced a
pseudonormalization of cortical excitability in ALS (Vucic et al., 2013).
However, in the current study, all patients were on steady state riluzole
treatment throughout, whichmay contribute to the lack of changes pre-
and post-ﬂecainide in cortical excitability. Further, while therapeutic
dose levels for the cardiac setting were achieved in the present study,
ﬂecainide levels in cerebrospinal ﬂuid may be lower than serum levels
(Romain et al., 1999), suggesting that higher doses may be required to
impact cortical excitability. Further studies with increased dosing
ranges may be required to comment on clinical efﬁcacy.
4.3. Safety and Efﬁcacy
The present study has established the safety of ﬂecainide in ALS,
achieved via careful patient monitoring and preemptive cardiac screen-
ing. In appropriately selected patients, ﬂecainide has a good safety
proﬁle, although should be avoided in patients with coronary artery or
heart disease as it has been demonstrated to increase the risk of deathTable 4
Reported adverse events. Reported as a number of patients with at least one event of the
particular type and percentage of all patients in each treatment group.
Adverse event Flecainide N = 24 Placebo N = 26
Dizziness 9 (38%) 6 (23%)
Tremor 8 (33%) 7 (27%)
Nausea 5 (21%) 3 (12%)
Diarrhoea 4 (17%) 4 (15%)
Chest pain 1 (4%) 2 (8%)
Palpitations 2 (8%) 2 (8%)
Coughing 7 (29%) 9 (35%)
Dry mouth 12 (50%) 10 (38%)
Difﬁculty sleeping 8 (33%) 9 (35%)
Excessive sleepiness 12 (50%) 5 (19%)
Joint pain 10 (42%) 8 (31%)
Muscle pain 10 (42%) 13 (50%)in this cohort (Aliot et al., 2011). Flecainide must also be used with
caution in patients with liver or kidney dysfunction. Critically all
patients in this series were formally reviewed by a cardiologist prior
to ﬂecainide administration to rule out any cardiac or other contraindi-
cations. Patients in the ﬂecainide group did not report signiﬁcant
adverse effects and there were no deaths attributed to ﬂecainide use.
Although ﬂecainide was tolerated and safe, there was no mea-
sureable beneﬁt in the primary outcomemeasure nor inmeasures of re-
spiratory function and motor function. The recruitment levels achieved
in the study were not as high as anticipated, particularly in light of the
variability between patients. While patients were recruited frommulti-
ple sites Australia-wide, the need for all assessments to be undertaken
at a single site may have affected the number of patients able to partic-
ipate. In addition to facilitate recruitment the study inclusion criteria
allowed patients with disease duration of up to 5 years to be recruited.
However, the neuroprotective effects of therapeutic agents may peak
in the earlier stages of the disease, with a therapeutic window prior to
irreversible motor neuron degeneration. A curvilinear rate of decline
in ALS-FRS-r has also been reported, with the rates of decline being
greatest during the ﬁrst 18 months of symptom onset and during the
terminal stages of illness (Gordon et al., 2007). Accordingly, these fac-
tors may contribute to the lack of signiﬁcant modulation in ALS-FRS-r.
However despite these limitations, the study identiﬁed signiﬁcant
biological activity of ﬂecainide at the peripheral nerve level.
4.4. Conclusions
While this double-blind, randomised controlled trial of the Na+
channel blocker ﬂecainide versus placebo did not identify any changes
in the primary outcome measure, rate of decline in the ALS-FRS-r,
ﬂecainide was safe and no safety concerns were identiﬁed. Flecainide
did not promote peripheral axonal degeneration but appeared to
modulate axonal function in ALS patients, stabilizing axonal excitability
and reducing decline in the neurophysiological index. These signiﬁcant
biological effects at the peripheral nerve level may warrant further
investigation to determine the signiﬁcance of reduced decline in the
neurophysiological index and changes in peripheral axonal excitability.
There are many challenges in conducting clinical trials in ALS cohorts,
including patient recruitment and loss to follow-up. Accordingly, the
present study was underpowered to make a clear statement regarding
clinical efﬁcacy of ﬂecainide in this population. It remains to be
determined the signiﬁcance of these effects on survival and long term
functional outcomes in ALS.
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